Targeted Treatment for Gastrointestinal Stromal Tumors
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
Progress Against Cancer
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has metastasized.
The new year began with the good news that death rates from cancer are continuing their steady decline. A study released this week by the American Cancer Society showed that from 2016 to 2017, the most recent year for which statistics are available, the cancer death rate declined by 2.2 percent—the largest single-year decline ever recorded. From 1991 to 2017, the cancer death rate has fallen 29 percent, equaling 2.9 million fewer cancer deaths.
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted therapies.
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words “karkinos” or “karkinoma,” which stem from the Greek word for “crab.” Today, the word "cancer" is used to describe hundreds of different types of this disease. As our understanding of cancer continues to grow, prevention, detection, and treatment advancements continue to evolve.
The FDA approved a molecularly targeted therapeutic for patients with advanced or metastatic urothelial cancer.
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the...
The FDA approved the immune checkpoint inhibitor pembrolizumab in combination with the molecularly targeted therapeutic lenvatinib for women with advanced endometrial cancer.
The most impactful and informative cancer reporting and essays of 2019 selected by the editors of Cancer Today magazine.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More